Prothena Announces Leadership Team Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Prothena Corp (PRTA) PT Lowered to $31 at BofA Securities
October 1, 2024 6:05 AM EDTBofA Securities analyst Tazeen Ahmad lowered the price target on Prothena Corp (NASDAQ: PRTA) to $31.00 (from $33.00) while maintaining a Neutral rating.
The analyst comments "We connected with management following the late Friday announcement that CMO, Hideki Garren, MD, PhD was leaving the company. Garren joined Roche as the new head of Neurology Product Development. CEO Gene Kinney stated that Garren has created a strong team at Prothena (PRTA). The company... More



